UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
SEC File No. 0-11472
------------
CUSIP No. 257782 10 2
--------------
(CHECK ONE): [ ] Form 10-K and Form 10-KSB [ ] Form 20-F Form 11-K
[X] Form 10-Q and Form 10-QSB [ ] Form N-SAR
For Period Ended: September 30, 2001
----------------------
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended:
----------------------------
NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS
VERIFIED ANY INFORMATION CONTAIN HEREIN.
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
- ------------------------------------------------------------------------------
PART I -- REGISTRANT INFORMATION
Donlar Biosyntrex Corporation
- ------------------------------------------------------------------------------
Full Name of Registrant
Biomune Systems, Inc.
- ------------------------------------------------------------------------------
Former Name if Applicable
6502 South Archer Road
- ------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)
Bedford Park, Illinois 60501
- ------------------------------------------------------------------------------
City, State and Zip Code
PART II -- RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)
[X] (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual report, transition report
on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof, will
be filed on or before the fifteenth calendar day following the
prescribed due date; or the subject quarterly report or transition
report on Form 10-Q, or portion thereof will be filed on or before the
fifth calendar day following the prescribed due date; and
[ ] (c) The accountant"s statement or other exhibit required by Rule 12b-25
(c) has been attached if applicable.
PART III -- NARRATIVE
State below in reasonable detail the reasons why Forms 10-K and 10-KSB, 20-F,
11-K, 10-Q and 10-QSB, "SAR, or the transition report or portion thereof, could
not be filed within the prescribed time period.
The quarterly report of the registrant on form 10-QSB could not be filed because
of delays encountered in finalizing the financial information.
PART IV -- OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Larry Koskan (708) 563-9200
- ------------------------ ------------------- -----------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If answer is no,
identify report(s). X Yes No
--- ---
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof? X Yes No
--- ---
If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
Due to the transaction with Donlar Corporation, it is anticipated that
significant changes in the results of operations from the quarterly period
ending on March 31, 2000 will be reflected by the earnings statements to be
included in this Form 10-QSB. A reasonable estimate of the results cannot
be made at this time.
================================================================================
DONLAR BIOSYNTREX CORPORATION
- --------------------------------------------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: November 15, 2001 By:/s/ Larry Koskan
------------------------ -------------------------------------
Larry Koskan,
President and Chief Executive Officer